Scholarlink

<p>Oral minoxidil is increasingly being used off-label in children to treat various conditions, including hair disorders and refractory hypertension. Despite its growing application, concerns regarding its safety and efficacy remain. This systematic review and meta-analysis assess oral minoxidil’s benefits and risks in pediatric patients across various dosages. Following the screening of 625 articles, 13 met the inclusion criteria, comprising a total of 364 pediatric patients. In the meta-analysis, adverse events occurred in 25.2% of patients with hair disorders (<i>P</i> = 0.009) and 26.1% of patients with refractory hypertension (<i>P</i> &lt; 0.001), with high heterogeneity (I<sup>2</sup> = 94–95%). Improvement in hair density was seen in 59.5% of patients (<i>P</i> &lt; 0.001, I<sup>2</sup> = 68%), while hair loss stabilization occurred in 24.3% (<i>P</i> &lt; 0.001, I<sup>2</sup> = 52%). These findings suggest that OM may represent a safer and more effective option for pediatric patients. Further large-scale, randomized controlled trials are recommended to confirm these results and establish optimal dosing guidelines.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety and use of oral minoxidil in pediatric patients: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2025年8月9日

查看全文
  • Omar M. Alassaf,
  • Layan M. Almutairi,
  • Albatul Majdi Tumbukani,
  • Razan S. Alhumaidi,
  • Abdulkarim M. Alawdah,
  • Samia N. Almutairi,
  • Salman B. Albadr,
  • Khamael F. Aljabri,
  • Joud A. Alyousef,
  • Hanin J. Mobarki,
  • Renad R. Almutairi,
  • Rose K. Aljuaid,
  • Osama M. Alsharif

摘要

Oral minoxidil is increasingly being used off-label in children to treat various conditions, including hair disorders and refractory hypertension. Despite its growing application, concerns regarding its safety and efficacy remain. This systematic review and meta-analysis assess oral minoxidil’s benefits and risks in pediatric patients across various dosages. Following the screening of 625 articles, 13 met the inclusion criteria, comprising a total of 364 pediatric patients. In the meta-analysis, adverse events occurred in 25.2% of patients with hair disorders (P = 0.009) and 26.1% of patients with refractory hypertension (P < 0.001), with high heterogeneity (I2 = 94–95%). Improvement in hair density was seen in 59.5% of patients (P < 0.001, I2 = 68%), while hair loss stabilization occurred in 24.3% (P < 0.001, I2 = 52%). These findings suggest that OM may represent a safer and more effective option for pediatric patients. Further large-scale, randomized controlled trials are recommended to confirm these results and establish optimal dosing guidelines.